Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 9/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.39 |
| ▸ | LIPC | P11150 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.36 |
| ▸ | ITGAV | P06756 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6135632 | 0.91 | ITGB3 (0.34) | ITGB3ITGA2BCES2FUCA1SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL6135130 | 0.84 | SLC6A2 (0.34) | ITGB3ITGA2BSLC6A4SLC6A2 | |
| Trifluoroacetic Acid SCHEMBL6134245 | 0.84 | GABRP (0.35) | FUCA1SLC6A4SLC6A2 | |
| SCHEMBL3020121 | 0.83 | CHRM1 (0.43) | SLC6A4SLC6A2GNAI3GNAO1GNAI1 | |
| Trifluoroacetic Acid SCHEMBL23466733 | 0.83 | CHRNB2 (0.38) | LIPCLIPGSLC6A4SLC6A2 | |
| Trifluoroacetic Acid SCHEMBL22729422 | 0.82 | LIPC (0.39) | LIPCLIPGCES2GNAI3GNAO1 | |
| Trifluoroacetic Acid SCHEMBL4010515 | 0.81 | SLC6A2 (0.33) | SLC6A4SLC6A2CHRM2 | |
| SCHEMBL4239877 | 0.78 | GNAO1 (0.43) | GNAI3GNAO1GNAI1 | |
| SCHEMBL20487794 | 0.77 | GNAO1 (0.46) | GNAI3GNAO1GNAI1 | |
| SCHEMBL9741247 | 0.77 | GNAO1 (0.46) | GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | ITGB3 1732/4885ITGA2B 3776/4885LIPC 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.